Effect of MDR1 gene promoter methylation in patients with ulcerative colitis

International Journal of Molecular Medicine

Volumn 23, Issue 4, 2009, Pages 521-527

  Tahara, Tomomitsu ^a   Shibata, Tomoyuki ^a   Nakamura, Masakatsu ^a   Yamashita, Hiromi ^a   Yoshioka, Daisuke ^a   Okubo, Masaaki ^a   Maruyama, Naoko ^a   Kamano, Toshiaki ^a   Kamiya, Yoshio ^a   Nakagawa, Yoshihito ^a   Fujita, Hiroshi ^a   Nagasaka, Mitsuo ^a   Iwata, Masami ^a   Takahama, Kazuya ^a   Watanabe, Makoto ^a   Hirata, Ichiro ^a   Arisawa, Tomiyasu ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

MDR1 methylation; Polymorphism; Ulcerative colitis

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DISEASE DURATION; DNA METHYLATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; ILEUM; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM MUCOSA; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 67649451991     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000160     Document Type: Article

References (38)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738, 1987.
2. Ho GT, Moodie FM and Satsangi J: Multidrug resistance 1 gene (P-glycoprotein170): an important determinant in gastrointestinal disease? Gut 52: 759-766, 2003.
3. Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D and Gale JD: Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J Pharmacol 143: 590-598, 2004.
4. -/-mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. Immunol Res 31: 151-160, 2005.
5. Kalitsky-Szirtes J, Shayeqanpour A, Brocks DR and Piquette-Miller M: Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispo 32: 20-27, 2004.
6. Buyse M, Radeva G, Bado A and Farinotti R: Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 69: 1745-1754, 2005.
7. Satsangi J, Parkes M, Louis E, et al: Two stage genome-wide search ininflammatory bowel disease provides evidence for susceptibility loci onchromosomes 3, 7 and 12. Nat Genet 14: 199-202, 1996.
8. Brant SR, Panhuysen CI, Nicolae D, et al: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 73: 1282-1292, 2003.
9. Schwab M, Schaeffeler E, Marx C, et al: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33, 2003.
10. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000.
11. Langmann T, Moehle C, Mauerer R, et al: Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127: 26-40, 2004.
12. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE and Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 4: 536-540, 1994.
13. Ahuja N, Li Q, Mohan AL, Baylin SB and Issa JP: Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 23: 5489-5494, 1998.
14. Sato F, Harpaz N, Shibata D, et al: Hypermethylation of the p14 (ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 62: 1148-1151, 2002.
15. Issa JP, Ahuja N, Toyota M, Bronner MP and Brentnall TA: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61: 3573-3577, 2001.
16. Bian YS, Osterheld MC, Fontolliet C, Bosman FT and Benhattar J: p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 122: 1113-1121, 2002.
17. Wong DJ, Paulson TG, Prevo LJ, et al: p16 (INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61: 8284-8289, 2001.
18. Kaneto H, Sasaki S, Yamamoto H, et al: Detection of hyper-methylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 48: 372-377, 2001.
19. Osuga T, Sakaeda T, Nakamura T, et al: MDR1 C3435T polymorphism is predictive of later onset of ulcerative colitis in Japanese. Biol Pharm Bull 29: 324-329, 2006.
20. Nakamura T, Sakaeda T, Horinouchi M, et al: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duoden enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71: 297-303, 2002.
21. Podolsky DK: Inflammatory bowel disease 2. N Engl J Med 325: 928-937, 1991.
22. Langholz E, Munkholm P, Davidsen M and Binder V: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107: 3-11, 1994.
23. Van Rijnsoever M, Grieu F, Elsaleh H, Joseph D and Iacopetta B: Characterisation of colorectal cancers showing hyper-methylation at multiple CpG islands. Gut 51: 797-802, 2002.
24. Tada Y, Wada M, Kuroiwa K, et al: MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6: 4618-4627, 2000.
25. Arisawa T, Tahara T, Shibata T, et al: Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach. J Gastroenterol Hepatol 22: 943-948, 2007.
26. Tahara T, Arisawa T, Shibata T, et al: Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion 75: 54-61, 2007.
27. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J and Sych Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13: 259-263, 2003.
28. Wang FY, Arisawa T, Tahara T, et al: Aberrant DNA methylation in ulcerative colitis without neoplasia. Hepatogastroenterology 55: 62-65, 2008.
29. Higgins CF: ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992.
30. Van Veen HW and Konings WN: The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta 1365: 31-36, 1998.
31. Dean M, Rzhetsky A and Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166, 2001.
32. Callen DF, Baker E, Simmers RN, Seshadri R and Roninson IB: Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 77: 142-144, 1987.
33. Van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD and Lewis CM; Genome scan meta-analysis group of the IBD International Genetics Consortium: Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 1: 763-770, 2004.
34. Ho GT, Nimmo ER, Tenesa A, et al: Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128: 288-296, 2005.
35. Moss SF and Blaser MJ: Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol 2: 90-97, 2005.
36. Kim RB, Leake BF, Choo EF, et al: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70: 189-199, 2001.
37. Fellay J, Marzolini C, Meaden ER, et al: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359: 30-36, 2002.
38. Hitzl M, Drescher S, van der Kuip H, et al: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetic 11: 293-298, 2001.